| Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ... New England Journal of Medicine 367 (12), 1098-1107, 2012 | 2087 | 2012 |
| Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New england journal of medicine 376 (3), 209-220, 2017 | 1998 | 2017 |
| Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis RJ Fox, DH Miller, JT Phillips, M Hutchinson, E Havrdova, M Kita, M Yang, ... New England Journal of Medicine 367 (12), 1087-1097, 2012 | 1602 | 2012 |
| Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ... The Lancet 380 (9856), 1819-1828, 2012 | 1295 | 2012 |
| Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ... The lancet 380 (9856), 1829-1839, 2012 | 1284 | 2012 |
| A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis G Giovannoni, G Comi, S Cook, K Rammohan, P Rieckmann, ... New England Journal of Medicine 362 (5), 416-426, 2010 | 1185 | 2010 |
| Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial C Confavreux, P O'Connor, G Comi, MS Freedman, AE Miller, TP Olsson, ... The Lancet Neurology 13 (3), 247-256, 2014 | 691 | 2014 |
| 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study P O'Connor, M Filippi, B Arnason, G Comi, S Cook, D Goodin, HP Hartung, ... The Lancet Neurology 8 (10), 889-897, 2009 | 517 | 2009 |
| Placebo-controlled trial of oral laquinimod for multiple sclerosis G Comi, D Jeffery, L Kappos, X Montalban, A Boyko, MA Rocca, M Filippi New England Journal of Medicine 366 (11), 1000-1009, 2012 | 447 | 2012 |
| Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial R Gold, G Giovannoni, K Selmaj, E Havrdova, X Montalban, EW Radue, ... The Lancet 381 (9884), 2167-2175, 2013 | 339 | 2013 |
| Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis O Khan, P Rieckmann, A Boyko, K Selmaj, R Zivadinov, ... Annals of neurology 73 (6), 705-713, 2013 | 306 | 2013 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 284 | 2017 |
| Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ... Neurology 89 (11), 1107-1116, 2017 | 240 | 2017 |
| Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? F Barkhof, HE Hulst, J Drulovic, BMJ Uitdehaag, K Matsuda, R Landin Neurology 74 (13), 1033-1040, 2010 | 167 | 2010 |
| Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage M Filippi, MA Rocca, E Pagani, N De Stefano, D Jeffery, L Kappos, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (8), 851-858, 2014 | 141 | 2014 |
| Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial G Giovannoni, R Gold, K Selmaj, E Havrdova, X Montalban, EW Radue, ... The Lancet Neurology 13 (5), 472-481, 2014 | 106 | 2014 |
| Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study DH Miller, RJ Fox, JT Phillips, M Hutchinson, E Havrdova, M Kita, ... Neurology 84 (11), 1145-1152, 2015 | 82 | 2015 |
| Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients G Giovannoni, JA Cohen, AJ Coles, HP Hartung, E Havrdova, KW Selmaj, ... Neurology 87 (19), 1985-1992, 2016 | 69 | 2016 |
| Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials C Sampaio, J Bronzova, RA Hauser, AE Lang, O Rascol, SV van de Witte, ... Movement disorders 26 (8), 1464-1476, 2011 | 55 | 2011 |
| Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate … O Khan, P Rieckmann, A Boyko, K Selmaj, N Ashtamker, MD Davis, ... Multiple Sclerosis Journal 23 (6), 818-829, 2017 | 37 | 2017 |
